Orforglipron (Foundayo) in 2026: FDA-Approved Oral GLP-1 — ATTAIN Trial Data, Dosage & Comparisons

Orforglipron, the first oral GLP-1 approved with no food or water restrictions, is one of 2026's fastest-rising peptide searches. Here's the ATTAIN trial data, dosage, side effects, and how it stacks up against tirzepatide, semaglutide, and retatrutide.